{"groups":[{"description":"paclitaxel, gemcitabine, and oxaliplatin:\n\n1. Paclitaxel 170 mg/m2 IV d 1 14 days\n2. Gemcitabine 800 mg/m2 IV d 1 14 days\n3. Oxaliplatin 100 mg/m2 IV d 1 14 days","id":"FG000","title":"Paclitaxel, Gemcitabine, and Oxaliplatin"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Alternative therapy received"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"non-compliance"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"19"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Recruitment for this study opened in November 2004 and closed in June 2012. All subjects were seen and treated in the medical clinics at the University of Southern California and Los Angeles General Medical Center."}